Under New Leadership, Dicerna Focuses on Raising Interest from Investors, Partners

Dicerna recently announced that its CEO had stepped down and will be replaced by company Co-Founder Doug Fambrough. He was a general partner at VC firm Oxford Bioscience Partners, an early investor in Sirna Therapeutics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories